The Evolution of TIL Therapy
As an early mover in TIL therapy, Grit Bio is advancing TIL in China while contributing to global innovation.
Back to TIL TherapyFirst Isolation of TILs
TIL pioneer Dr. Steven Rosenberg first isolated TILs from multiple murine tumor models, laying the foundation for subsequent research.
Clinical Breakthrough
TILs were used clinically to treat metastatic melanoma, demonstrating objective responses and substantial antitumor activity.
A Landmark Complete Response
Patient advocate Melinda Bachini achieved a complete response following TIL treatment for advanced intrahepatic cholangiocarcinoma.
Expansion of Clinical Research by Iovance
Beginning in 2015, Iovance conducted studies in melanoma, cervical cancer and non-small cell lung cancer.
Grit Bio GT101
GT101 became the first TIL therapy approved for clinical trial in China, marking a new stage in China's clinical exploration of TIL therapy.
FDA Approval and Pivotal Development
The FDA approved Iovance's lifileucel based on the C-144-01 study. Grit Bio initiated a pivotal Phase II clinical trial of GT101 for metastatic or recurrent cervical cancer.
IND Milestones
Regulatory milestones were achieved for GT101 combination therapy and GT307.